Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
National Cancer Institute (P01CA03942, P30CA196521)
Pediatric Cancer Foundation
- License Information
-
More Information
Article History
First Online: 17 November 2020
Declarations
:
: National Cancer Institute (P01CA03942 and P30CA196521), Pediatric Cancer Foundation.
: SK and AE report no conflicts of interest. JEL reports royalties from a GVHD biomarker patent, research support from Biogen, Incyte, and Kamada, and consulting fees from Bluebird, Incyte, Ironwood, Mesoblast, Novartis, Omeros, Oncoimmue, Talaris, and X4 Pharmaceuticals.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: JEL was invited to provide the review. SK, AE, and JEL performed the literature review and wrote the manuscript. All authors take responsibility for the final version of the paper.
